Dyne Therapeutics
Tracked across 4 events · 39 articles · First seen Jun 03, 2026 · Last active Sep 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Dyne Therapeutics announced the completion of enrollment in the registrational expansion cohort of its ACHIEVE trial for zeleciment basivarsen, a significant step towards potential market approval and commercialization of a treatment for Myotonic Dystrophy Type 1 (DM1). This milestone could positively impact the company's stock price and future revenue streams.
Jun 03, 2026 · 6 articles
Business
Impact: Dyne raised $431.4 million through the offering, strengthening its balance sheet to fund clinical programs.
Jul 21, 2026 · 6 articles
Regulatory
Impact: Dyne Therapeutics received FDA clearance for its IND application for DYNE-302, allowing it to initiate a Phase 1 trial for FSHD. This expands its clinical pipeline and validates its FORCE platform.
Jul 28, 2026 · 6 articles
Business
Novartis announced on September 8, 2026 that its Phase III HARBOR study of del-desiran, an antibody oligonucleotide conjugate for myotonic dystrophy type 1 (DM1), failed to show statistically significant improvement versus placebo on the primary…
Impact: Dyne Therapeutics shares fell about 30% in US premarket trading as the del-desiran failure weighed on sentiment toward muscular dystrophy drug developers.
Sep 08, 2026 · 21 articles
40
Dyne Therapeutics shares fellNovartis del-desiran Phase...
ERGEN INTELLIGENCE
Track Dyne Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard